Facilitating Innovative Nuclear Diagnostics Act of 2023

S 1544, the Facilitating Innovative Nuclear Diagnostics Act of 2023, requires Medicare to make separate payments for certain high-cost diagnostic radiopharmaceuticals starting January 1, 2024. It applies to drugs meeting a $500 per day cost threshold (rising annually with inflation), defined as FDA-approved nuclear imaging drugs launched after 2008. Payments will use existing Medicare pricing mechanisms - either average sales price or wholesale acquisition cost - to ensure separate coverage without bundling. This directly affects Medicare beneficiaries receiving these specific nuclear diagnostics and the hospitals/providers billing Medicare for them. The bill does not change patient costs or coverage eligibility but alters Medicare's payment structure for these drugs.